How to Read Your Semaglutide Lab Results

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

When you start semaglutide therapy, your doctor will likely order baseline blood work and periodic follow-up labs to monitor your metabolic health. Semaglutide affects multiple body systems—from blood sugar regulation to cholesterol metabolism—so knowing which lab values matter most helps you make informed decisions about your treatment plan. PlexusDx guides patients through this process by connecting lab findings to personalized dosing and genetic insights.

Key Blood Markers to Monitor During Semaglutide Treatment

Fasting glucose measures your blood sugar level after 8+ hours without food, providing a snapshot of baseline metabolic control. Most patients on semaglutide see fasting glucose drop by 15–30 mg/dL within the first 8 weeks of treatment. A normal fasting glucose ranges from 70–100 mg/dL, though your doctor may set individual targets based on your health history.

Hemoglobin A1C (HbA1c) reflects your average blood sugar over 2–3 months, making it a more reliable long-term indicator than a single fasting measurement. Semaglutide typically lowers A1C by 1–2 percentage points in the first three months, with continued improvement as your dose increases. If your baseline A1C is above 7%, a reduction toward this target signals better glucose stability and lower diabetes risk.

Lipid Panel Changes and What They Mean

Your lipid panel includes total cholesterol, LDL (bad cholesterol), HDL (good cholesterol), and triglycerides. Semaglutide users frequently experience triglyceride reductions of 20–40% because the medication improves how your body processes dietary fats. Lower triglycerides reduce cardiovascular risk and inflammation, even before significant weight loss occurs.

LDL cholesterol may drop modestly during semaglutide therapy, particularly if you lose weight and improve insulin sensitivity. HDL cholesterol sometimes rises slightly, creating a more favorable cholesterol ratio. Your doctor should compare current lipid results to your baseline to confirm whether additional heart-health interventions are needed alongside semaglutide therapy.

Liver and Kidney Function Tests During GLP-1 Therapy

Liver enzymes (ALT and AST) and kidney markers (creatinine and eGFR) form part of routine monitoring because rapid weight loss can temporarily stress these organs. Most patients show stable or improving kidney function within 3–6 months of semaglutide use, especially as weight decreases and blood pressure normalizes. Liver enzymes typically remain normal unless fatty liver disease was severe at baseline.

Elevated kidney markers are rare on semaglutide alone but warrant closer monitoring if you have a pre-existing kidney condition. Your lab results should show stable creatinine and eGFR over consecutive months, confirming that the medication is well-tolerated by your filtration system. If kidney function declines, your healthcare provider may adjust your semaglutide dose or investigate other contributing factors.

How to Understand Your Results and Plan Next Steps

Comparing your baseline labs to your current results reveals the direction and magnitude of metabolic change. A 10–15 mg/dL drop in fasting glucose after one month shows your body is responding well to semaglutide, while plateaued glucose levels may signal the need for a dose increase or lifestyle adjustment. PlexusDx recommends reviewing labs every 4–8 weeks during the first 3 months, then quarterly once stable.

Your Precision Peptide Genetic Test can help explain why your lab responses may differ from typical averages. Genetic variants in GLP1R, GIPR, and FTO pathways influence how efficiently your body processes semaglutide and handles glucose metabolism. If your results lag behind expected improvements, genetic insights might reveal whether oral delivery, a dual-compound protocol, or microdose adjustments could optimize your response. Schedule a follow-up with your PlexusDx provider to discuss lab trends and refine your personalized treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is a normal fasting glucose level, and how much should it drop on semaglutide?

Normal fasting glucose is 70–100 mg/dL. Most semaglutide users see a drop of 15–30 mg/dL within the first 8 weeks, though individual response varies based on genetics and starting baseline. PlexusDx monitors your fasting glucose trends to guide dose adjustments and confirm metabolic improvement.

Why do triglycerides drop so quickly on semaglutide?

Semaglutide slows gastric emptying and improves insulin sensitivity, helping your body process dietary fats more efficiently. This mechanism often delivers 20–40% triglyceride reductions before significant weight loss occurs, lowering inflammation and cardiovascular risk early in treatment.

How often should I get blood work while on semaglutide?

PlexusDx recommends baseline labs before starting, then every 4–8 weeks during the first 3 months while doses are increasing. After reaching a stable dose, quarterly labs (every 3 months) are sufficient to monitor ongoing metabolic health and detect any changes in kidney or liver function.

Can semaglutide damage my kidneys or liver?

Semaglutide is well-tolerated by most patients, and kidney or liver damage is rare. Rapid weight loss can temporarily stress these organs, but most users show stable or improving kidney and liver function within 3–6 months. Regular lab monitoring catches any early concerns and allows your PlexusDx provider to adjust treatment as needed.

How can the Precision Peptide Genetic Test explain my lab results?

The PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R pathways—genes that influence how efficiently your body responds to semaglutide and processes glucose.

Related Reading

• How To Read Peptide Genetic Test Results
• How To Read Methylation Test Results
• Medvi Semaglutide
• Bioverse Semaglutide

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.